Key Ongoing Clinical Trials

November 3, 2026

Disclaimer

- The information contained on these pages is accurate as of November 3, 2026 to the best of Pfizer's knowledge. Pfizer assumes no obligation to update this information.

- This presentation includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. There can be no guarantees with respect to pipeline products that clinical studies will be successful, that products will advance to the next phase of development, that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in or implied by the forward-looking statements. Additional information regarding these and other factors can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in Pfizer's subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.

- Study starts on clinicaltrials.gov are based on first subject first visit (FSFV), which may differ from Pfizer milestone tracking, which defines study start as first subject first dose (FSFD).

- Visit www.pfizer.com/pipeline, Pfizer's online database where you can learn more about our portfolio of investigational medicines and vaccines and find out more about our Research and Development efforts around the world.

Atirmociclib (PF-07220060): CDK4 inhibitor

Trial	Population	Enrollment	Design	Endpoints	Status
FOURLIGHT-3 Phase III NCT06760637	HR+/HER2- advanced or metastatic breast cancer with no prior treatment	1,035	Atirmociclib + letrozole vs. investigator's choice of CDK4/6i + letrozole	Primary endpoint: PFS Secondary endpoints: OS, OR, DoR	Study Start: 1Q25 PCD: 1Q29
FOURLIGHT-4 Phase III NCT07890597	ER+/HER2- early-stage breast cancer with medium or high risk of recurrence	*3800 (est.)*	Atirmociclib + giredestrant vs. giredestrant + placebo	Primary endpoint: iBCFS, iDFS Secondary endpoints: DRFS, OS	Study Start: 4Q26 PCD: 2Q32

* Trials shown represent selected key clinical studies for this program and are not intended to be an exhaustive list of all ongoing or completed clinical trials. Enrollment numbers are actual unless otherwise labeled as estimated, indicated by italics. Enrollment and primary completion date are estimates based on clinicaltrials.gov data as of November 3, 2026. Study starts on clinicaltrials.gov are based on first subject first visit (FSFV), which may differ from Pfizer milestone tracking, which defines study start as first subject first dose (FSFD). See 'Glossary' on slide 20 for terms and definitions.

Disitamab vedotin (PF-08046051): HER2-directed antibody-drug conjugate

Trial	Population	Enrollment	Design	Endpoints	Status
DV-001 Phase III NCT05911295	Previously untreated locally advanced or metastatic HER2-expressing urothelial carcinoma	412	Disitamab vedotin + pembrolizumab vs. gemcitabine + cisplatin or carboplatin	Primary endpoint: PFS, OS Secondary endpoints: ORR, DoR	Study Start: 3Q23 PCD: 1Q27

* Trials shown represent selected key clinical studies for this program and are not intended to be an exhaustive list of all ongoing or completed clinical trials. Enrollment numbers are actual unless otherwise labeled as estimated, indicated by italics. Enrollment and primary completion date are estimates based on clinicaltrials.gov data as of November 3, 2026. Study starts on clinicaltrials.gov are based on first subject first visit (FSFV), which may differ from Pfizer milestone tracking, which defines study start as first subject first dose (FSFD). See 'Glossary' on slide 20 for terms and definitions.

ELREXFIO (elranatamab): BCMA–CD3 bispecific antibody

Trial	Population	Enrollment	Design	Endpoints	Status
MAGNETISMM-5 Phase III NCT05020236	Double-class exposed relapsed/refractory multiple myeloma	*893 (est.)*	Elranatamab alone vs. elranatamab + daratumumab vs. daratumumab + pomalidomide + dexamethasone	Primary endpoint: PFS Secondary endpoints: OS, ORR, DoR, TTR, CRR, DoCR	Study Start: 4Q21 PCD: 1Q26 [**Readout 2Q26**]
MAGNETISMM-32 Phase III NCT06152575	Double-class exposed relapsed/refractory multiple myeloma post-CD38 directed therapy	*492 (est.)*	Elranatamab alone vs. investigator's choice of combination therapy	Primary endpoint: PFS Secondary endpoints: OS, ORR, DoR, VGPR, CRR, DoCR, TTR	Study Start: 1Q24 PCD: 3Q26 **[Readout 4Q26]**
MAGNETISMM-6 Phase III NCT05623020	Transplant-ineligible newly diagnosed multiple myeloma	*1,060 (est.)*	Elranatamab + daratumumab + lenalidomide vs. daratumumab + bortezomib + lenalidomide + dexamethasone	Primary endpoint: PFS, MRD-negative rate at 12 months Secondary endpoints: OS, ORR, CRR, TTR, DoR, DoCR	Study Start: 4Q22 PCD: 4Q30
MAGNETISMM-7 Phase III NCT05317416	Post-transplant newly diagnosed multiple myeloma	854	Elranatamab vs. lenalidomide	Primary endpoint: PFS Secondary endpoints: OS, CRR, DoCR	Study Start: 1Q22 PCD: 3Q27

Pfizer

* Trials shown represent selected key clinical studies for this program and are not intended to be an exhaustive list of all ongoing or completed clinical trials. Enrollment numbers are actual unless otherwise labeled as estimated, indicated by italics. Enrollment and primary completion date are estimates based on clinicaltrials.gov data as of November 3, 2026. Study starts on clinicaltrials.gov are based on first subject first visit (FSFV), which may differ from Pfizer milestone tracking, which defines study start as first subject first dose (FSFD). See 'Glossary' on slide 20 for terms and definitions.

Fetrastobart vedotin (PF-08046054): PD-L1-directed antibody-drug conjugate

Trial	Population	Enrollment	Design	Endpoints	Status
PADL1NK-005 Phase III NCT07144280	Previously-treated PD-L1+ non-small cell lung cancer	*680 (est.)*	Fetrastobart vedotin vs. docetaxel	Primary endpoint: OS Secondary endpoints: PFS, ORR, DoR	Study Start: 3Q25 PCD: 1Q28

* Trials shown represent selected key clinical studies for this program and are not intended to be an exhaustive list of all ongoing or completed clinical trials. Enrollment numbers are actual unless otherwise labeled as estimated, indicated by italics. Enrollment and primary completion date are estimates based on clinicaltrials.gov data as of November 3, 2026. Study starts on clinicaltrials.gov are based on first subject first visit (FSFV), which may differ from Pfizer milestone tracking, which defines study start as first subject first dose (FSFD). See 'Glossary' on slide 20 for terms and definitions.

Mevrometostat (PF-06821497): EZH2 inhibitor

Trial	Population	Enrollment	Design	Endpoints	Status
MEVPRO-1 Phase III NCT06551324	Metastatic castration-resistant prostate cancer after progression on prior abiraterone acetate treatment	609	Mevrometostat + enzalutamide vs. investigator's choice (enzalutamide or docetaxel)	Primary endpoint: rPFS Secondary endpoints: OS, ORR, DoR	Study Start: 4Q24 PCD: 1Q27
MEVPRO-2 Phase III NCT06629779	Metastatic castration-resistant prostate cancer (ARPI-naïve)	*900 (est.)*	Mevrometostat + enzalutamide vs. enzalutamide + placebo	Primary endpoint: rPFS Secondary endpoints: OS, TTPP, ORR, DoR	Study Start: 4Q24 PCD: 3Q27
MEVPRO-3 Phase III NCT07028853	Metastatic castration-sensitive prostate cancer (ARPI-naïve)	*1,000 (est.)*	Mevrometostat + enzalutamide vs. enzalutamide + placebo	Primary endpoint: rPFS Secondary endpoints: OS, OR, DoR, PSA progression	Study Start: 3Q25 PCD: 3Q28

* Trials shown represent selected key clinical studies for this program and are not intended to be an exhaustive list of all ongoing or completed clinical trials. Enrollment numbers are actual unless otherwise labeled as estimated, indicated by italics. Enrollment and primary completion date are estimates based on clinicaltrials.gov data as of November 3, 2026. Study starts on clinicaltrials.gov are based on first subject first visit (FSFV), which may differ from Pfizer milestone tracking, which defines study start as first subject first dose (FSFD). See 'Glossary' on slide 20 for terms and definitions.

PADCEV (enfortumab vedotin): Nectin-4 directed antibody-drug conjugate

Trial	Population	Enrollment	Design	Endpoints	Status
EV-309 Phase III NCT07566156	Muscle-invasive bladder cancer (bladder sparing)	*390 (est.)*	Enfortumab vedotin + pembrolizumab vs. concurrent chemoradiotherapy	Primary endpoint: BI-EFS, OS Secondary endpoints: cCR, MFS, DFS	Study Start: 2Q26 PCD: 1Q30

* Trials shown represent selected key clinical studies for this program and are not intended to be an exhaustive list of all ongoing or completed clinical trials. Enrollment numbers are actual unless otherwise labeled as estimated, indicated by italics. Enrollment and primary completion date are estimates based on clinicaltrials.gov data as of November 3, 2026. Study starts on clinicaltrials.gov are based on first subject first visit (FSFV), which may differ from Pfizer milestone tracking, which defines study start as first subject first dose (FSFD). See 'Glossary' on slide 20 for terms and definitions.

Prifetrastat (PF-07248144): KAT6 epigenetic modifier

Trial	Population	Enrollment	Design	Endpoints	Status
KATSIS-1 Phase III NCT07062965	HR+/HER2- advanced/metastatic breast cancer (post-CDK4/6)	*400 (est.)*	Prifetrastat + fulvestrant vs. everolimus + exemestane or fulvestrant	Primary endpoint: PFS Secondary endpoints: OS, OR, DoR, CBR	Study Start: 3Q25 PCD: 3Q27

* Trials shown represent selected key clinical studies for this program and are not intended to be an exhaustive list of all ongoing or completed clinical trials. Enrollment numbers are actual unless otherwise labeled as estimated, indicated by italics. Enrollment and primary completion date are estimates based on clinicaltrials.gov data as of November 3, 2026. Study starts on clinicaltrials.gov are based on first subject first visit (FSFV), which may differ from Pfizer milestone tracking, which defines study start as first subject first dose (FSFD). See 'Glossary' on slide 20 for terms and definitions.

Sigvotatug vedotin (PF-08046047): Integrin beta-6-directed antibody-drug conjugate

= trial not yet listed on clinicaltrials.gov

Trial	Population	Enrollment	Design	Endpoints	Status
SigVie-003 Phase III NCT06758401	PD-L1 high, locally advanced, unresectable or metastatic non-small cell lung cancer	*714 (est.)*	Sigvotatug vedotin + pembrolizumab vs. pembrolizumab alone	Primary endpoint: OS, PFS Secondary endpoints: ORR, DoR	Study Start: 3Q25 PCD: 3Q28
Phase III	1L non-small cell lung cancer (TPS all comers)	TBA	TBA	TBA	Study Start: Anticipated Next 12 Months (*as of 11/3/26*)

* Trials shown represent selected key clinical studies for this program and are not intended to be an exhaustive list of all ongoing or completed clinical trials. Enrollment numbers are actual unless otherwise labeled as estimated, indicated by italics. Enrollment and primary completion date are estimates based on clinicaltrials.gov data as of November 3, 2026. Study starts on clinicaltrials.gov are based on first subject first visit (FSFV), which may differ from Pfizer milestone tracking, which defines study start as first subject first dose (FSFD). See 'Glossary' on slide 20 for terms and definitions.

Tivunatamig (PF-08634404): PD-1xVEGF bispecific antibody

= trial not yet listed on clinicaltrials.gov

Trial	Population	Enrollment	Design	Endpoints	Status
SYMBIOTIC-GI-03 Phase III NCT07222800	Treatment-naïve metastatic colorectal cancer	*800 (est.)*	PF-08634404 + chemotherapy vs. bevacizumab + chemotherapy	Primary endpoint: OS, PFS Secondary endpoints: ORR, DoR	Study Start: 4Q25 PCD: 1Q30
SYMBIOTIC-GYN-18 Phase III NCT07578649	Advanced or recurrent MMR-proficient endometrial cancer	*600 (est.)*	PF-08634404 + chemotherapy vs. pembrolizumab + chemotherapy	Primary endpoint: PFS Secondary endpoints: OS, ORR, DoR	Study Start: 4Q26 PCD: 2Q29
SYMBIOTIC-LUNG-01 Phase III NCT07222566	Locally advanced or metastatic non-small cell lung cancer	*1,410 (est.)*	PF-08634404 + chemotherapy vs. pembrolizumab + chemotherapy	Primary endpoint: OS, PFS Secondary endpoints: ORR, DoR	Study Start: 1Q26 PCD: 1Q29
SYMBIOTIC-LUNG-04 Phase II/III NCT07226999	Extensive-stage small cell lung cancer	*550 (est.)*	PF-08634404 + chemotherapy vs. atezolizumab + chemotherapy	Primary endpoint: ORR, OS Secondary endpoints: DoR, PFS	Study Start: 4Q25 PCD: 2Q30
SYMBIOTIC-GI-16 Phase II/III NCT07392892	Locally advanced or metastatic gastroesophageal cancer	*840 (est.)*	PF-08634404 + chemotherapy vs. nivolumab + chemotherapy	Primary endpoint: ORR, PFS, OS Secondary endpoints: DoR, PFS	Study Start: 2Q26 PCD: 3Q31
Phase III	1L metastatic urothelial cancer	TBA	TBA – combination with PADCEV (enfortumab vedotin)	TBA	Study Start: Anticipated Next 12 Months (*as of 11/3/26*)
Phase III	Early-stage non-small cell lung cancer	TBA	TBA	TBA	Study Start: Anticipated Next 12 Months (*as of 11/3/26*)

* Trials shown represent selected key clinical studies for this program and are not intended to be an exhaustive list of all ongoing or completed clinical trials. Enrollment numbers are actual unless otherwise labeled as estimated, indicated by italics. Enrollment and primary completion date are estimates based on clinicaltrials.gov data as of November 3, 2026. Study starts on clinicaltrials.gov are based on first subject first visit (FSFV), which may differ from Pfizer milestone tracking, which defines study start as first subject first dose (FSFD). See 'Glossary' on slide 20 for terms and definitions.

Berobenatide (PF-08653944): GLP-1 receptor agonist

Trial	Population	Enrollment	Design	Endpoints	Status
VESPER-4 Phase III NCT07311850	Obesity or overweight with weight-related comorbidities excluding type 2 diabetes	3,578	Once-weekly berobenatide vs. placebo	Primary endpoint: Change from baseline in body weight	Study Start: 4Q25 PCD: 3Q27
VESPER-5 Phase III NCT07400653	Obesity or overweight with type 2 diabetes	1,078	Once-weekly berobenatide vs. placebo	Primary endpoint: Change from baseline in body weight	Study Start: 1Q26 PCD: 4Q27
VESPER-6 Phase III NCT07595549	Obesity or overweight	*954 (est.)*	Once-monthly berobenatide vs. placebo	Primary endpoint: Change from baseline in body weight	Study Start: 2Q26 PCD: 2Q28
VESPER-SWITCH Phase III NCT07845500	Obesity or overweight (taking semaglutide or tirzepatide)	*660 (est.)*	Switch from weekly semaglutide or tirzepatide to monthly berobenatide	Primary endpoint: Change from baseline in body weight	Study Start: 3Q26 PCD: 1Q28
VESPER-JW Phase III NCT07794761	Obesity or overweight (Japan)	*180 (est.)*	Once-weekly berobenatide vs. placebo	Primary endpoint: Change from baseline in body weight	Study Start: 4Q26 PCD: 1Q29
VESPER-JM Phase III NCT07794774	Obesity or overweight (Japan)	*197 (est.)*	Once-monthly berobenatide vs. placebo	Primary endpoint: Change from baseline in body weight	Study Start: 3Q26 PCD: 1Q29
Phase III NCT07792954	Obesity or overweight (China)	*300 (est.)*	Once-weekly berobenatide vs. placebo	Primary endpoint: Change from baseline in body weight	Study Start: 3Q26 PCD: 1Q28
Phase III NCT07874633	Obesity or overweight (China)	*432 (est.)*	Once-monthly berobenatide vs. placebo	Primary endpoint: Change from baseline in body weight	Study Start: 4Q26 PCD: 2Q28

Pfizer

* Trials shown represent selected key clinical studies for this program and are not intended to be an exhaustive list of all ongoing or completed clinical trials. Enrollment numbers are actual unless otherwise labeled as estimated, indicated by italics. Enrollment and primary completion date are estimates based on clinicaltrials.gov data as of November 3, 2026. Study starts on clinicaltrials.gov are based on first subject first visit (FSFV), which may differ from Pfizer milestone tracking, which defines study start as first subject first dose (FSFD). See 'Glossary' on slide 20 for terms and definitions.

Berobenatide (PF-08653944): GLP-1 receptor agonist

= trial not yet listed on clinicaltrials.gov

Trial	Population	Enrollment	Design	Endpoints	Status
VESPER-OSA 1 Phase III NCT07823608	Obstructive sleep apnea or obesity or overweight who use a PAP machine	*258 (est.)*	Once-monthly berobenatide vs. placebo	Primary endpoint: Change from baseline in AHI Secondary endpoint: Change from baseline in body weight	Study Start: 3Q26 PCD: 2Q28
VESPER-OSA 2 Phase III NCT07881757	Obstructive sleep apnea or obesity or overweight who do not use a PAP machine	*258 (est.)*	Once-monthly berobenatide vs. placebo	Primary endpoint: Change from baseline in AHI Secondary endpoint: Change from baseline in body weight	Study Start: 4Q26 PCD: 2Q28
Phase III	Knee osteoarthritis (and obesity or overweight)	TBA	TBA	TBA	Study Start: Anticipated Next 12 Months (*as of 11/3/26*)

* Trials shown represent selected key clinical studies for this program and are not intended to be an exhaustive list of all ongoing or completed clinical trials. Enrollment numbers are actual unless otherwise labeled as estimated, indicated by italics. Enrollment and primary completion date are estimates based on clinicaltrials.gov data as of November 3, 2026. Study starts on clinicaltrials.gov are based on first subject first visit (FSFV), which may differ from Pfizer milestone tracking, which defines study start as first subject first dose (FSFD). See 'Glossary' on slide 20 for terms and definitions.

PF-08653945: Amylin analog with dual amylin and calcitonin receptor activity

Trial	Population	Enrollment	Design	Endpoints	Status
SOLIS-1 Phase II NCT07575932	Obesity or overweight	940	PF-08653945 vs. placebo; PF-08653945 + berobenatide vs. placebo; PF-08653945 + berobenatide or berobenatide vs. placebo	Primary endpoint: Percent change from baseline in body weight	Study Start: 2Q26 PCD: 3Q27
Phase I/II NCT06924320	Obesity or overweight including with or without type 2 diabetes	201	Single and multiple ascending dose berobenatide + PF-08653945 vs. placebo	Primary endpoint: Occurrence of TEAEs	Study Start: 1Q25 PCD: 3Q26
Phase I NCT07022977	Obesity or overweight	144	Single and multiple ascending dose PF-08653945 vs. placebo (weekly followed by monthly)	Primary endpoint: Occurrence of TEAEs Secondary endpoint: Percent change from baseline in body weight	Study Start: 4Q24 PCD: 2Q26

* Trials shown represent selected key clinical studies for this program and are not intended to be an exhaustive list of all ongoing or completed clinical trials. Enrollment numbers are actual unless otherwise labeled as estimated, indicated by italics. Enrollment and primary completion date are estimates based on clinicaltrials.gov data as of November 3, 2026. Study starts on clinicaltrials.gov are based on first subject first visit (FSFV), which may differ from Pfizer milestone tracking, which defines study start as first subject first dose (FSFD). See 'Glossary' on slide 20 for terms and definitions.

Ponsegromab (PF-06946860): GDF15 monoclonal antibody

Trial	Population	Enrollment	Design	Endpoints	Status
RIVER-mPDAC Phase II/III NCT06989437	Cachexia and metastatic pancreatic ductal adenocarcinoma	*982 (est.)*	Ponsegromab (lower/higher dose) vs. placebo	Primary endpoint: Percent change from baseline in body weight for ponsegromab compared to placeb, Change from baseline in Functional Assessment of Anorexia/Cachexia Therapy 5-item Anorexia Symptom Scale scores	Study Start: 4Q25 PCD: 1Q28

* Trials shown represent selected key clinical studies for this program and are not intended to be an exhaustive list of all ongoing or completed clinical trials. Enrollment numbers are actual unless otherwise labeled as estimated, indicated by italics. Enrollment and primary completion date are estimates based on clinicaltrials.gov data as of November 3, 2026. Study starts on clinicaltrials.gov are based on first subject first visit (FSFV), which may differ from Pfizer milestone tracking, which defines study start as first subject first dose (FSFD). See 'Glossary' on slide 20 for terms and definitions.

NURTEC (rimegepant): CGRP receptor antagonist

Trial	Population	Enrollment	Design	Endpoints	Status
Phase IV NCT07609914	Redosing (acute treatment of migraine)	*400 (est.)*	Rimegepant (acute treatment + potential second dose within 24 hours)	Primary endpoint: Incidence of TEAEs	Study Start: 2Q26 PCD: 2Q28
Phase III NCT06641466	Intermittent prevention of menstrual migraine	*723 (est.)*	Rimegepant vs. comparator (placebo dosing/standard of care for acute treatment as needed)	Primary endpoint: Change in number of migraine days	Study Start: 1Q25 PCD: 4Q26
Phase III NCT07729462	Prevention of chronic migraine	*400 (est.)*	Once-daily rimegepant vs. placebo	Primary endpoint: Change in number of monthly migraine days	Study Start: 3Q26 PCD: 4Q28
Phase III NCT06616194	Adolescents with chronic migraine	*636 (est.)*	Rimegepant vs. placebo	Primary endpoint: Number of migraine days per month	Study Start: 4Q24 PCD: 1Q30
Phase III NCT05156398	Migraine prevention (children and adolescents)	*640 (est.)*	Rimegepant vs. placebo	Primary endpoint: Change from baseline in mean number of migraine days per month	Study Start: 1Q22 PCD: 1Q29
Phase III NCT04743141	Acute migraine treatment (children and adolescents)	*600 (est.)*	Rimegepant monotherapy	Primary endpoint: Frequency and severity of on-treatment and TEAEs	Study Start: 2Q21 PCD: 3Q30
Phase III NCT04649242	Moderate to severe migraine (children and adolescents)	*2,100 (est.)*	Rimegepant vs. placebo	Primary endpoint: Pain freedom	Study Start: 1Q21 PCD: 1Q29

Pfizer

* Trials shown represent selected key clinical studies for this program and are not intended to be an exhaustive list of all ongoing or completed clinical trials. Enrollment numbers are actual unless otherwise labeled as estimated, indicated by italics. Enrollment and primary completion date are estimates based on clinicaltrials.gov data as of November 3, 2026. Study starts on clinicaltrials.gov are based on first subject first visit (FSFV), which may differ from Pfizer milestone tracking, which defines study start as first subject first dose (FSFD). See 'Glossary' on slide 20 for terms and definitions.

LB6V (PF-07307405): Lyme disease vaccine candidate

Trial	Population	Enrollment	Design	Endpoints	Status
Phase III NCT07226882	Healthy participants	207	LB6V (4 doses, different time points) and placebo	Primary endpoint: Safety, tolerability, immunogenicity	Study Start: 4Q25 PCD: 1Q28
Phase III NCT07500506	Healthy participants vaccinated with 4 doses of LB6V	*1,712 (est.)*	LB6V vs. placebo	Primary endpoint: Safety, tolerability, immunogenicity	Study Start: 2Q26 PCD: 4Q26

* Trials shown represent selected key clinical studies for this program and are not intended to be an exhaustive list of all ongoing or completed clinical trials. Enrollment numbers are actual unless otherwise labeled as estimated, indicated by italics. Enrollment and primary completion date are estimates based on clinicaltrials.gov data as of November 3, 2026. Study starts on clinicaltrials.gov are based on first subject first visit (FSFV), which may differ from Pfizer milestone tracking, which defines study start as first subject first dose (FSFD). See 'Glossary' on slide 20 for terms and definitions.

PCV25 (PF-07872412): 25-valent pneumococcal infection vaccine candidate

Trial	Population	Enrollment	Design	Endpoints	Status
Phase III NCT07573462	Healthy infants	*2,400 (est.)*	PCV25 vs. 20vPnC	Primary endpoint: Safety, tolerability	Study Start: 2Q26 PCD: 4Q28
Phase III NCT07629440	Healthy infants	*3,230 (est.)*	PCV25 vs. 20vPnC	Primary endpoint: Safety, tolerability, immunogenicity	Study Start: 2Q26 PCD: 2Q29
Phase III NCT07660198	Healthy children & adolescents	*1,200 (est.)*	PCV25 vs. 20vPnC (catch-up regimen)	Primary endpoint: Safety, tolerability, immunogenicity	Study Start: 2Q26 PCD: 4Q27
Phase III NCT07794748	Healthy adults	*4,670 (est.)*	PCV25 (three lots) vs. 20vPnC (lot consistency study)	Primary endpoint: Safety, tolerability, immunogenicity	Study Start: 3Q26 PCD: 2Q27

* Trials shown represent selected key clinical studies for this program and are not intended to be an exhaustive list of all ongoing or completed clinical trials. Enrollment numbers are actual unless otherwise labeled as estimated, indicated by italics. Enrollment and primary completion date are estimates based on clinicaltrials.gov data as of November 3, 2026. Study starts on clinicaltrials.gov are based on first subject first visit (FSFV), which may differ from Pfizer milestone tracking, which defines study start as first subject first dose (FSFD). See 'Glossary' on slide 20 for terms and definitions.

PF-07831694: *Clostridioides difficile* vaccine candidate

Trial	Population	Enrollment	Design	Endpoints	Status
BEETHOVEN Phase III NCT07282665	Adults aged 65+ years	*32,500 (est.)*	PF-07831694 vs. saline placebo	Primary endpoint: Incidence of CDI	Study Start: 4Q25 PCD: 4Q28

* Trials shown represent selected key clinical studies for this program and are not intended to be an exhaustive list of all ongoing or completed clinical trials. Enrollment numbers are actual unless otherwise labeled as estimated, indicated by italics. Enrollment and primary completion date are estimates based on clinicaltrials.gov data as of November 3, 2026. Study starts on clinicaltrials.gov are based on first subject first visit (FSFV), which may differ from Pfizer milestone tracking, which defines study start as first subject first dose (FSFD). See 'Glossary' on slide 20 for terms and definitions.

LITFULO (ritlecitinib): JAK3/TEC inhibitor

Trial	Population	Enrollment	Design	Endpoints	Status
TRANQUILLO Phase III NCT05583526	Nonsegmental vitiligo (active and stable)	607	Ritlecitinib (50 mg) vs. placebo	Primary endpoint: F-VASI75, T-VASI50	Study Start: 4Q22 PCD: 1Q26 **[Readout 3Q26]**
TRANQUILLO 2 Phase III NCT06072183	Nonsegmental vitiligo	1,571	Ritlecitinib vs. placebo (52 weeks) with dose-up/dose-down 52-week extension	Primary endpoint: F-VASI75, T-VASI50	Study Start: 4Q23 PCD: 3Q27 **[Readout 3Q26]**
TRANQUILLO LTE Phase III NCT06163326	Nonsegmental vitiligo (participants who completed treatment in parent study)	394	Ritlecitinib (50 mg or 100 mg) or placebo (randomized withdrawal or dose-up titration)	Primary endpoint: Safety and tolerability Secondary endpoint: F-VASI75, T-VASI50	Study Start: 1Q24 PCD: 1Q27
Phase III NCT07733765	Moderate alopecia areata (participants 12+ years)	*336 (est.)*	Ritlecitinib (50 mg) vs. placebo followed by 24-week extension with potential for dose escalation (100 mg)	Primary endpoint: SALT score	Study Start: 3Q26 PCD: 2Q28
Phase III NCT07029711	Severe alopecia areata (pediatric participants 6 to <12 years)	208	Ritlecitinib (50 mg or 100 mg) vs. placebo	Primary endpoint: SALT score	Study Start: 3Q25 PCD: 4Q26

* Trials shown represent selected key clinical studies for this program and are not intended to be an exhaustive list of all ongoing or completed clinical trials. Enrollment numbers are actual unless otherwise labeled as estimated, indicated by italics. Enrollment and primary completion date are estimates based on clinicaltrials.gov data as of November 3, 2026. Study starts on clinicaltrials.gov are based on first subject first visit (FSFV), which may differ from Pfizer milestone tracking, which defines study start as first subject first dose (FSFD). See 'Glossary' on slide 20 for terms and definitions.

Tilrekimig (PF-07275315): anti-IL-4/ IL-13/ TSLP

Trial	Population	Enrollment	Design	Endpoints	Status
Phase III NCT07765888	Moderate to severe atopic dermatitis	*375 (est.)*	Tilrekimig vs. placebo	Primary endpoint: EASI75	Study Start: 3Q26 PCD: 1Q28
Phase III NCT07783425	Moderate to severe atopic dermatitis	*1,375 (est.)*	Tilrekimig vs. dupilumab vs. placebo	Primary endpoint: EASI75; vIGA	Study Start: 3Q26 PCD: 3Q28
Phase III NCT07772921	Severe asthma	*1,100 (est.)*	Tilrekimig vs. placebo	Primary endpoint: Annualized asthma exacerbation rate	Study Start: 3Q26 PCD: 2Q29
Phase III NCT07869043	Severe asthma	*1,100 (est.)*	Tilrekimig vs. placebo	Primary endpoint: Annualized asthma exacerbation rate	Study Start: 3Q26 PCD: 2Q29
Phase III NCT07839884	Moderate to severe chronic obstructive pulmonary disease	*1,360 (est.)*	Tilrekimig (continuation study)	Primary endpoint: Safety & tolerability	Study Start: 3Q26 PCD: 2Q34
Phase II/III NCT07363694	Moderate to severe chronic obstructive pulmonary disease	*1,156 (est.)*	Tilrekimig vs. placebo	Primary endpoint: FEV1 at week 24, rate of moderate or severe ECOPD	Study Start: 1Q26 PCD: 4Q30

* Trials shown represent selected key clinical studies for this program and are not intended to be an exhaustive list of all ongoing or completed clinical trials. Enrollment numbers are actual unless otherwise labeled as estimated, indicated by italics. Enrollment and primary completion date are estimates based on clinicaltrials.gov data as of November 3, 2026. Study starts on clinicaltrials.gov are based on first subject first visit (FSFV), which may differ from Pfizer milestone tracking, which defines study start as first subject first dose (FSFD). See 'Glossary' on slide 20 for terms and definitions.

Glossary

- 20vPnC = 20-valent pneumococcal conjugate vaccine
- AHI = Apnea-Hypopnea Index
- ARPI = Androgen receptor pathway inhibitor
- BCMA = B-cell maturation antigen
- BI-EFS = Bladder-intact event free survival
- CBR = Clinical benefit response
- cCR = Complete clinical response
- CD3 = Cluster of differentiation 3
- CD38 = Cluster of differentiation 38
- CDI = Clostridioides difficile infection
- CDK4 = Cyclin-dependent kinase 4
- CGRP = Calcitonin gene-related peptide
- CR = Complete response
- CRR = Complete response rate
- DCR = Disease control rate
- DFS = Disease free survival
- DoCR = Duration of complete response
- DoR = Duration of response
- DRFS = Disease recurrence-free survival
- EASI75 = Eczema and Severity Index 75
- ECOPD = Exacerbation of chronic obstructive pulmonary disease
- ER = Estrogen receptor
- EZH2 = Enhancer of zeste homolog 2
- FEV1 = Forced expiratory volume in 1 second
- F-VASI75 = Facial Vitiligo Area Scoring Index 75
- GDF15 = Growth differentiation factor 15
- GLP-1 = Glucagon-like peptide-1
- HER2 = Human epidermal growth factor receptor 2
- HR = Hormone receptor
- iBCFS = Invasive breast cancer-free survival
- iDFS = Invasive disease-free survival
- IL-13 = Interleukin 13
- IL-4 = Interleukin 4
- JAK3 = Janus kinase 3
- KAT6 = Lysine acetyltransferase 6
- MFS = Metastasis-free survival
- MMR = Mismatch repair
- MRD= Minimal residual disease
- ORR = Objective response rate
- OS = Overall survival
- PAP = Positive airway pressure
- PCD = Primary completion date
- PD-1 = Programmed cell death protein 1
- PD-L1 = Programmed death-ligand 1
- PFS = Progression free survival
- PSA = Prostate specific antigen
- rPFS = Radiographic progression free survival
- SALT = Severity of Alopecia Tool
- TBA = To be announced
- TEAEs = Treatment-emergent adverse events
- TEC = Tyrosine-protein kinase
- TPS = Tumor Proportion Score
- TSLP = Thymic stromal lymphopoietin
- TTPP = Time to pain progression
- TTR = Time to response
- T-VASI50 = Total Vitiligo Area Scoring Index 50
- VEGF = Vascular endothelial growth factor
- VGPR = Very good partial response
- vIGA = Validated Investigator Global Assessment